Most-favored-nation drug pricing is the idea that Americans should not pay more for a medicine than the lowest price the same manufacturer accepts in another wealthy country. It moved from a talking point to actual prices you can look up in 2026.
The gap between what has been announced and what you can buy today is wide, though, and it matters if you are the one paying. This guide separates the two, using prices verified directly on TrumpRx.gov and the manufacturers’ own pharmacy pages on September 6, 2026.
What Most-Favored-Nation Pricing Means
The premise: the U.S. funds a disproportionate share of global pharmaceutical profits while other developed countries negotiate their prices down. MFN pricing pegs the American price to the lowest price paid by a comparable developed nation.
Executive Order 14297, signed May 12, 2025, made that policy. It directed HHS to communicate MFN price targets to manufacturers and, in Section 4, to facilitate direct-to-consumer purchasing programs for manufacturers that sell to American patients at the MFN price. It also reserved harder tools in case manufacturers did not move: a rulemaking plan to impose MFN pricing, drug importation waivers, and antitrust enforcement.
Those harder tools have not been used. What happened instead was a sequence of voluntary company-by-company deals, and a government-run storefront to display the resulting prices.
Where the Policy Stands as of September 2026
Here is the timeline as documented in White House releases, each of which is linked in the sources.
- May 12, 2025: Executive Order 14297 signed.
- July 31, 2025: Letters sent to 17 leading manufacturers laying out required steps.
- December 1, 2025: A trade agreement with the United Kingdom raising the net price of new prescription drugs there by 25%, framed as making other countries pay their share.
- February 5, 2026: TrumpRx.gov launches with drugs from the first five manufacturers to sign: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer, covering 40 branded medicines.
- May 18, 2026: TrumpRx expands to more than 600 generic medications, integrating cash prices from Amazon Pharmacy, Cost Plus Drugs and GoodRx.
- August 31, 2026: Nine more manufacturers sign (Alcon, Astellas, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva and UCB), bringing the total to 26 manufacturers covering about 89% of the branded drug market. Those nine also committed at least $19.6 billion collectively to U.S. manufacturing.
The critical distinction for a consumer: none of this is a regulation. It is contract and announcement. A manufacturer that changes its offer terms next quarter is not violating a rule, and several of the live offers carry explicit language reserving the right to modify or cancel at any time.
What TrumpRx Is, and What It Actually Sells
TrumpRx.gov is a price-listing and routing site. It is not a pharmacy. Medicare.gov states this in plain language on its drug-costs page: you can’t buy drugs directly from TrumpRx.
There are two mechanisms behind the listings. For some drugs, TrumpRx generates a discount coupon (with a BIN, PCN, group and member ID) that you present at a retail pharmacy, the same plumbing a commercial discount card uses. For others, it hands you off to the manufacturer’s own direct-pay pharmacy. Zepbound, for example, routes to LillyDirect, and semaglutide products route to NovoCare Pharmacy.
That means TrumpRx is best understood as a shop window over the manufacturers’ existing self-pay channels, at the same prices those channels already charge. It is genuinely useful as a comparison tool. It is not a separate, cheaper store.
The site displayed a banner of “$700,000,000+ Saved for Americans” on September 6, 2026. Treat that as a government claim about its own program rather than an independently measured figure.
What You Can Buy Today, and at What Price
TrumpRx listed 80 branded “Presidential deals” when checked on September 6, 2026. The four headline products, with the site’s own “original price” comparison:
| Drug | MFN price | Original price |
|---|---|---|
| Wegovy pill | $149/month | $1,349 |
| Wegovy pen | $199/month | $1,349 |
| Ozempic | $199/month | $1,028 |
| Zepbound | $299/month | $1,087 |
Each of these was independently confirmed on the manufacturer’s own site the same day. NovoCare Pharmacy lists Wegovy pill starting at $149 a month and Wegovy pen starting at $199. Zepbound’s own savings page lists $299 a month for the KwikPen or the vial (not the single-dose pen).
Two of these carry a catch worth reading carefully. Novo Nordisk’s terms price the Wegovy pen and Ozempic pen at $199 for the first two monthly fills of the lower doses, running through December 31, 2026, and then $349 a month for most doses. Ozempic 2 mg goes to $499 and Wegovy HD 7.2 mg to $399. So the $199 you see advertised is an introductory rate for new self-pay patients, not a steady-state price. For a full breakdown of the GLP-1 landscape, see the cheapest way to get a GLP-1.
Beyond GLP-1s, the deepest discounts on the list as of September 6, 2026 were on drugs most people have never heard of. Combigan (glaucoma) at $10.00 against $204.13. Cetrotide (fertility) at $22.50 against $316.12. Striverdi Respimat (COPD) at $35.00 against $276.00. Bevespi at $50.65 against $458.05. Toujeo (basal insulin) starting at $35.00 against $428.57. Farxiga starting at $35.00 against $377.82. Humira Pen at $950.00 against $6,922.62.
The generics section works differently. Prices there are not MFN deals at all. They are cash prices pulled from Amazon Pharmacy, Cost Plus Drugs and GoodRx, and they load by ZIP code, so there is no single national number for atorvastatin or metformin on the site. It is a comparison shopper, and it is worth using alongside GoodRx and SingleCare rather than instead of them.
What Is Still Just an Announcement
Be honest about the gaps. Several things have been announced without a live purchase path a consumer can use today.
The August 31, 2026 agreements with nine mid-sized manufacturers describe MFN pricing for state Medicaid programs and for future new medicines. Neither of those is a price a cash patient can buy at right now.
The White House has said drugs from other signing companies will be added to TrumpRx “in the coming months” since the February launch. With 26 manufacturers signed and 80 branded deals listed, most of the branded market covered by these agreements still has no TrumpRx price.
And the “89% of the branded drug market” figure describes manufacturer coverage, not drug coverage. A company signing an MFN agreement does not mean every one of its drugs is discounted.
Where a promised price has no live purchase path, the practical answer is unchanged: check manufacturer assistance programs, compare mail-order pharmacy and PfizerForAll style direct channels, and price the generic.
Who Should Use It and Who Should Skip It
MFN prices are aimed squarely at cash payers. Every offer checked carries self-pay terms that exclude anyone with Medicare, Medicaid, TRICARE, VA or other government coverage, and bar you from submitting the cost to insurance or counting it toward a deductible or out-of-pocket limit.
If you are uninsured or your commercial plan does not cover the drug, this is a real option and often the cheapest one. If you have Medicare, read the fine print twice. Medicare.gov is explicit: TrumpRx and other discount cards are not creditable coverage, and using them instead of your plan does not count toward your Medicare deductible or out-of-pocket maximum. Since Part D caps your annual out-of-pocket at $2,100 in 2026, paying cash outside the plan can leave you worse off across a full year even when the sticker price looks better.
There is one Medicare-specific carve-out worth knowing. CMS is running a short-term demonstration called the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027, giving eligible Part D beneficiaries certain GLP-1 drugs for a $50 copay. CMS states it operates outside the Part D benefit, so the deductible does not apply, none of the $50 counts toward your true out-of-pocket costs, and there is no low-income subsidy on it. See Medicare GLP-1 coverage for how that fits with plan coverage.
MFN Prices vs. Medicare’s Negotiated Prices
These two programs get conflated constantly. They are not the same thing.
| Most-favored-nation prices | Medicare negotiated prices | |
|---|---|---|
| Legal basis | Executive order plus voluntary agreements | Inflation Reduction Act statute |
| Who can use them | Cash payers; government beneficiaries excluded | Medicare Part D enrollees only |
| Price benchmark | Lowest price in comparable developed nations | CMS negotiation against therapeutic alternatives |
| Number of drugs | 80 branded deals listed on TrumpRx, plus generics | 25 drugs priced, 15 more in negotiation |
| Counts toward Part D deductible and cap | No | Yes |
| Can it change without notice | Yes, terms reserve the right to modify | No, prices are published annually by CMS |
Bottom Line
MFN pricing has produced real, checkable cash prices on a limited set of branded drugs, and for a cash-paying patient on Wegovy, Zepbound, Farxiga, Toujeo or a fertility drug, the savings are large and available today. But the mechanism is voluntary agreements, not law, the deepest headline discounts on GLP-1 pens are introductory rates that step up after two fills, and TrumpRx does not sell you anything. Look up your drug, note whether the price is a coupon or a manufacturer channel, read the duration terms, and if you have Medicare, compare it against what your plan charges before you pay cash.